Sumitomo Chemical India Ltd Q4 FY26 Results Analysis: EBITDA Margin Hits 20.72%, Debt-Free Balance Sheet
Sumitomo Chemical India Ltd's Q4 FY26 numbers came in mixed, with revenue of Rs. 683.74 Cr (+0.60% YoY) and PAT growth of +11.60% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | May 26, 2026 |
|---|---|
| Quarter | Q4 FY 2025-2026 |
| Revenue (Q4) | Rs. 683.74 Cr (+0.60% YoY) |
| PAT (Q4) | Rs. 111.32 Cr (+11.60% YoY) |
| EBITDA margin | 20.72% (+65 bps YoY) |
| EPS (Q4) | Rs. 2.23 (+11.50% YoY) |
| Market cap | Rs. 23,449.78 Cr |
| CMP | Rs. 469.60 |
Quarter Snapshot
Sumichem delivered on margin targets (20.72% EBITDA margin vs >20% target) but revenue growth was muted at +2.9% as pricing pressure offset volume gains. A debt-free balance sheet with Rs.1,221 Cr liquidity provides resilience, but working capital absorption and unresolved glyphosate regulation are near-term overhangs. The company's strong domestic and export volume growth suggests underlying demand is intact, with pricing stabilization being the key catalyst to watch.
Key Investment Insights
Key Positives
- Q4 FY26 revenue of Rs.6,837 Mn rebounded +20.4% QoQ after a weak Q3
- FY26 EBITDA margin of 20.72% exceeded management's >20% target
- PAT grew +11.6% YoY in Q4 FY26 to Rs.1,113 Mn
- Balance sheet is debt-free with Rs.1,221 Cr in cash and investments
- Trade receivables declined 6.1% YoY indicating improved collections
- Normalized FY26 PAT growth (adjusted for exceptional labour code charge) was +9.6% YoY
Risk Factors
- Revenue growth was just +2.9% for FY26 as pricing pressure (~17-18% realization decline) offset volume growth of 25%+
- Glyphosate regulatory overhang remains unresolved
- Capex of Rs.442 Mn was only 44% of the 15%-of-EBITDA target of Rs.1,006 Mn
- Net working capital absorbed Rs.71 Cr as inventories grew 8.9% and payables declined 18.8%
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.